Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer

References

• Du XL, Jiang T, Sheng XG, Li QS, Wang C, Yu H. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer. Eur J Radiol 2012; 81(11):3551-6; PMID:22521528; https://doi.org/10.1016/j.ejrad.2012.03.016
   PubMed Web of Science ®Google Scholar
• Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: Opportunities, progresses and challenges. J Hematol Oncol 2010; 3:7; PMID:20146807; https://doi.org/10.1186/1756-8722-3-7
   PubMed Web of Science ®Google Scholar
• Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363(10):943-53; PMID:20818904; https://doi.org/10.1056/NEJMoa0908806
   PubMed Web of Science ®Google Scholar
• Demir L, Yigit S, Sadullahoglu C, Akyol M, Cokmert S, Kucukzeybek Y, Alacacioglu A, Cakalagaoglu F, Tarhan MO. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma–is here a prognostic phenotype? Asian Pac J Cancer Prev 2014; 15(22):9739-45; PMID:25520097; https://doi.org/10.7314/APJCP.2014.15.22.9739
   PubMedGoogle Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26):2484-96; PMID:22204725; https://doi.org/10.1056/NEJMoa1103799
   PubMed Web of Science ®Google Scholar
• Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 2012; 10:174; PMID:22925189; https://doi.org/10.1186/1477-7819-10-174
   PubMed Web of Science ®Google Scholar
• Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol 2012; 33(6):2117-23; PMID:22875782; https://doi.org/10.1007/s13277-012-0471-7
   PubMed Web of Science ®Google Scholar
• Huang HN, Chiang YC, Cheng WF, Chen CA, Lin MC, Kuo KT. Molecular alterations in endometrial and ovarian clear cell carcinomas: Clinical impacts of telomerase reverse transcriptase promoter mutation. Mod Pathol 2015; 28(2):303-11; PMID:25081752; https://doi.org/10.1038/modpathol.2014.93
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian X, Liu J, Jiang X, Shen Y, Zhang L, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol 2015; 32(1):391; PMID:25433947; https://doi.org/10.1007/s12032-014-0391-z
   PubMed Web of Science ®Google Scholar
• Schluter B, Gerhards R, Strumberg D, Voigtmann R. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol 2010; 136(9):1389-400; PMID:20217132; https://doi.org/10.1007/s00432-010-0790-2
   PubMed Web of Science ®Google Scholar
• Joung YH, Na YM, Yoo YB, Darvin P, Sp N, Kang DY, Kim SY, Kim HS, Choi YH, Lee HK, et al. Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway. Int J Oncol 2014; 44(3):883-95; PMID:24402583; https://doi.org/10.3892/ijo.2014.2250
   PubMed Web of Science ®Google Scholar
• Dominguez E, Mauborgne A, Mallet J, Desclaux M, Pohl M. SOCS3-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury. J Neurosci 2010; 30(16):5754-66; PMID:20410127; https://doi.org/10.1523/JNEUROSCI.5007-09.2010
   PubMed Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G, Bishayee A. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta 2014; 1845(2):136-54; PMID:24388873; https://doi.org/10.1016/j.bbcan.2013.12.005
   PubMed Web of Science ®Google Scholar
• Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 2014; 13(12):3037-48; PMID:25319391; https://doi.org/10.1158/1535-7163.MCT-14-0077
   PubMed Web of Science ®Google Scholar
• Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SK. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett 2014; 347(1):54-64; PMID:24491408; https://doi.org/10.1016/j.canlet.2014.01.020
   PubMed Web of Science ®Google Scholar
• Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004; 23(46):7726-33; PMID:15361843; https://doi.org/10.1038/sj.onc.1207787
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366(15):1382-92; PMID:22452356; https://doi.org/10.1056/NEJMoa1105535
   PubMed Web of Science ®Google Scholar
• Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol 2012; 23(Suppl 10):x118-27; PMID:22987945; https://doi.org/10.1093/annonc/mds315
   PubMed Web of Science ®Google Scholar
• Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Jr., Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006; 107(11):2730-40; PMID:17063503; https://doi.org/10.1002/cncr.22293
   PubMed Web of Science ®Google Scholar
• Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68(2–3):154-61; PMID:16020953; https://doi.org/10.1159/000086958
   PubMed Web of Science ®Google Scholar
• Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93(5):552-6; PMID:16106267; https://doi.org/10.1038/sj.bjc.6602738
   PubMed Web of Science ®Google Scholar
• Baspinar S, Bircan S, Yavuz G, Kapucuoglu N. Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters. Pathol Res Pract 2013; 209(7):418-23; PMID:23722017; https://doi.org/10.1016/j.prp.2013.04.006
   PubMed Web of Science ®Google Scholar
• Dai J, Zhang PH, Liu PS, Qu HH. [Expressions and significance of cyclinD1 in epithelial ovarian cancer cell 3AO]. Zhonghua Yi Xue Za Zhi 2012; 92(5):351-3; PMID:22490843.
   PubMedGoogle Scholar
• McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, Varadharaj S, Zhang J, Hideg K, Houghton P, et al. Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience 2014; 1(3):216-28; PMID:25594014; https://doi.org/10.18632/oncoscience.26
   PubMedGoogle Scholar
• Zou M, Zhang X, Xu C. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells. Cell Oncol (Dordr) 2016; 39(1):47-57; PMID:26510945; https://doi.org/10.1007/s13402-015-0251-7
   PubMed Web of Science ®Google Scholar
• Setsu N, Kohashi K, Endo M, Yamamoto H, Tamiya S, Takahashi Y, Yamada Y, Ishii T, Matsuda S, Yokoyama R, et al. Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis. Int J Cancer 2013; 132(1):109-15; PMID:22644781; https://doi.org/10.1002/ijc.27655
   PubMed Web of Science ®Google Scholar
• Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, et al. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Mol Cancer Ther 2015; 14(4):1035-47; PMID:25646015; https://doi.org/10.1158/1535-7163.MCT-14-0800
   PubMed Web of Science ®Google Scholar
• Zhang MX, Zhao X, Wang ZG, Zhao WM, Wang YS. Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation. J Cancer Res Clin Oncol 2010; 136(7):981-8; PMID:20052595; https://doi.org/10.1007/s00432-009-0743-9
   PubMed Web of Science ®Google Scholar
• Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 2013; 288(36):26167-76; PMID:23902772; https://doi.org/10.1074/jbc.M113.477950
   PubMed Web of Science ®Google Scholar
• Hiwatashi K, Tamiya T, Hasegawa E, Fukaya T, Hashimoto M, Kakoi K, Kashiwagi I, Kimura A, Inoue N, Morita R, et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett 2011; 308(2):172-80; PMID:21624767; https://doi.org/10.1016/j.canlet.2011.04.024
   PubMed Web of Science ®Google Scholar
• Deng J, Jiao X, Liu H, Wu L, Zhang R, Wang B, Pan Y, Hao X, Liang H. Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer. Tumour Biol 2013; 34(6):3627-36; PMID:23824571; https://doi.org/10.1007/s13277-013-0944-3
   PubMed Web of Science ®Google Scholar
• Deng JY, Sun D, Liu XY, Pan Y, Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 2010; 16(42):5380-7; PMID:21072904; https://doi.org/10.3748/wjg.v16.i42.5380
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Sasako M, Mizusawa J, Hirota S, Ochiai A, Kushima R, Katai H, Tanaka Y, Fukushima N, Nashimoto A, et al. HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer 2015; 18(3):467-75; PMID:24993498; https://doi.org/10.1007/s10120-014-0398-3
   PubMed Web of Science ®Google Scholar
• K PM. WHO handbook for reporting results of cancer treatment. Br J Cancer 1982; 38(3):484-5.
   Google Scholar
• Nowak M, Szpakowski M, Malinowski A, Wieczorek A, Szpakowski A, Raczkowska Z, Maciolek-Blewniewska G, Laskowski J, Budzko W, Kolasa D. [Ovarian cancer. I. Epidemiology, symptoms, FIGO staging]. Ginekol Pol 2000; 71(9):1179-83; PMID:11082999
   PubMedGoogle Scholar